Advertisement

Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck

Published:February 26, 2022DOI:https://doi.org/10.1016/j.anl.2022.02.006

      Abstract

      Objective

      Real-world outcomes and prognostic factors in Japanese patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma (RMHNC) with an observation period of 1 year have been previously reported. The 1-year follow-up data have been subsequently accumulated, and the long-term real-world outcomes have been analyzed. This study aimed to investigate the 2-year long-term outcomes and prognostic factors associated with the response to nivolumab.

      Methods

      This was a multi-institutional retrospective study. In total, 88 RMHNC Japanese patients with squamous cell carcinoma who received nivolumab between May 2017 and May 2018 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and best overall response (BOR) were evaluated. Univariate and multivariable analyses were performed to identify the prognostic factors.

      Results

      The median follow-up periods for monitoring OS and PFS were 73.1 and 48.1 weeks, respectively. The median OS was 74.1 weeks, and the 2-year survival rate was 33.4%. The median PFS was 18.5 weeks, and the 2-year PFS rate was 22.5%. The BOR rate was 10.2%, 19.3%, 25.0%, and 44.3% in patients who achieved complete response, partial response, stable disease, and progressive disease (PD), respectively. Among the 88 patients with RMHNC, a total of 40 immune-related adverse events (irAEs) were reported in 30 patients. Four patients continued nivolumab, while 84 patients discontinued nivolumab at the data cut-off date. The most common reason for discontinuation was PD in 61 patients, irAEs in 14 patients, and patients’ wishes in 7 patients. Of the 61 patients who discontinued nivolumab because of PD, 28 patients received subsequent treatment. Statistical analyses revealed radiotherapy history, performance status, platinum-refractory carcinoma, irAEs, age, and post-nivolumab treatment as the important prognostic factors associated with OS in patients with RMHNC, and the magnitude of BOR was significantly associated with OS. Additionally, patients with subsequent treatment, including molecular targeted therapy and/or chemotherapy, had significantly prolonged OS compared to patients without subsequent treatment in cases with nivolumab discontinuation because of PD.

      Conclusion

      These findings could be a useful guide for future treatment strategies for head and neck carcinoma. Considering the limitations of our cohort, further larger-scale studies with long-term follow-up are needed to substantiate the results of this study.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Auris Nasus Larynx
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferris RL
        • Blumenschein G
        • Fayette J
        • Guigay J
        • Colevas AD
        • Licitra L
        • et al.
        Nivolumab for recurrent squamous-cell carcinoma of the head and neck.
        N Engl J Med. 2016; 375: 1856-1867https://doi.org/10.1056/nejmoa1602252
        • Kiyota N
        • Hasegawa Y
        • Takahashi S
        • Yokota T
        • Yen CJ
        • Iwae S
        • et al.
        A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
        Oral Oncol. 2017; 73: 138-146https://doi.org/10.1016/j.oraloncology.2017.07.023
        • Yen CJ
        • Kiyota N
        • Hanai N
        • Takahashi S
        • Yokota T
        • Iwae S
        • et al.
        Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
        Head Neck. 2020; 42: 2852-2862https://doi.org/10.1002/hed.26331
        • Hori R
        • Shinohara S
        • Kojima T
        • Kagoshima H
        • Kitamura M
        • Tateya I
        • et al.
        Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma.
        Cancers (Basel). 2019; 11https://doi.org/10.3390/cancers11091317
        • Kanda Y.
        Investigation of the freely available easy-to-use software “EZR” for medical statistics.
        Bone Marrow Transplant. 2013; 48: 452-458https://doi.org/10.1038/bmt.2012.244
        • Ferris RL
        • Blumenschein G
        • Fayette J
        • Guigay J
        • Colevas AD
        • Licitra L
        • et al.
        Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
        Oral Oncol. 2018; 81: 45-51https://doi.org/10.1016/j.oraloncology.2018.04.008
        • Matsuki T
        • Okamoto I
        • Fushimi C
        • Takahashi H
        • Okada T
        • Kondo T
        • et al.
        Real-world, long-term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best overall response: A retrospective multicenter study of 88 patients.
        Cancers (Basel). 2020; 12: 1-13https://doi.org/10.3390/cancers12113427
        • Matsuo M
        • Yasumatsu R
        • Masuda M
        • Toh S
        • Wakasaki T
        • Hashimoto K
        • et al.
        Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
        Oral Oncol. 2020; 101104525https://doi.org/10.1016/j.oraloncology.2019.104525
        • Hanai N
        • Shimizu Y
        • Kariya S
        • Yasumatsu R
        • Yokota T
        • Fujii T
        • et al.
        Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.
        Int J Clin Oncol. 2020; https://doi.org/10.1007/s10147-020-01829-0
        • McBride S
        • Sherman E
        • Jillian Tsai C
        • Baxi S
        • Aghalar J
        • Eng J
        • et al.
        Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma.
        J Clin Oncol. 2021; 39: 30-37https://doi.org/10.1200/JCO.20.00290
        • Liu Y
        • Dong Y
        • Kong L
        • Shi F
        • Zhu H
        • Yu J.
        Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.
        J Hematol Oncol. 2018; 11: 1-15https://doi.org/10.1186/s13045-018-0647-8
        • Demaria S
        • Golden EB
        • Formenti SC.
        Role of local radiation therapy in cancer immunotherapy.
        JAMA Oncol. 2015; 1: 1325-1332https://doi.org/10.1001/jamaoncol.2015.2756
        • Deng L
        • Liang H
        • Burnette B
        • Beckett M
        • Darga T
        • Weichselbaum RR
        • et al.
        Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
        J Clin Invest. 2014; 124: 687-695https://doi.org/10.1172/JCI67313
        • Dudnik E
        • Moskovitz M
        • Daher S
        • Shamai S
        • Hanovich E
        • Grubstein A
        • et al.
        Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data.
        Lung Cancer. 2018; 126: 217-223https://doi.org/10.1016/j.lungcan.2017.11.015
        • Yasumatsu R
        • Matsuo M
        • Wakasaki T
        • Masuda M
        • Takeuchi T
        • Manako T
        • et al.
        Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events.
        Acta Otolaryngol. 2020; 140: 1043-1048https://doi.org/10.1080/00016489.2020.1807601
        • Ueki Y
        • Takahashi T
        • Ota H
        • Shodo R
        • Yamazaki K
        • Horii A.
        Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma : prognostic value of combined performance status and modified Glasgow prognostic score.
        Eur Arch Oto-Rhino-Laryngology. 2020; 277: 2341-2347https://doi.org/10.1007/s00405-020-05945-5
        • Garde-Noguera J
        • Martin-Martorell P
        • De Julián M
        • Perez-Altozano J
        • Salvador-Coloma C
        • García-Sanchez J
        • et al.
        Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
        Clin Transl Oncol. 2018; 20: 1072-1079https://doi.org/10.1007/s12094-017-1829-5
        • Hussaini S
        • Chehade R
        • Boldt RG
        • Raphael J
        • Blanchette P
        • Maleki Vareki S
        • et al.
        Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis.
        Cancer Treat Rev. 2021; 92102134https://doi.org/10.1016/j.ctrv.2020.102134
        • Wu Q
        • Wang Q
        • Tang X
        • Xu R
        • Zhang L
        • Chen X
        • et al.
        Correlation between patients’ age and cancer immunotherapy efficacy.
        Oncoimmunology. 2019; 8: 1-9https://doi.org/10.1080/2162402X.2019.1568810
        • Kondo T
        • Okamoto I
        • Sato H
        • Koyama N
        • Fushimi C
        • Okada T
        • et al.
        Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
        Asia Pac J Clin Oncol. 2020; 16: 340-347https://doi.org/10.1111/ajco.13374
        • Saleh K
        • Daste A
        • Martin N
        • Pons-Tostivint E
        • Auperin A
        • Herrera-Gomez RG
        • et al.
        Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
        Eur J Cancer. 2019; 121: 123-129https://doi.org/10.1016/j.ejca.2019.08.026
        • Wakasaki T
        • Yasumatsu R
        • Uchi R
        • Taura M
        • Matsuo M
        • Komune N
        • et al.
        Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
        Auris Nasus Larynx. 2020; 47: 116-122https://doi.org/10.1016/j.anl.2019.05.001
        • Wakasaki T
        • Yasumatsu R
        • Masuda M
        • Takeuchi T
        • Manako T
        • Matsuo M
        • et al.
        Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
        Cancers (Basel). 2020; 12 (https://doi:): 2299https://doi.org/10.3390/cancers12082299
        • Park SE
        • Lee SH
        • Ahn JS
        • Ahn MJ
        • Park K
        • Sun JM.
        Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non–small cell lung cancer.
        J Thorac Oncol. 2018; 13: 106-111https://doi.org/10.1016/j.jtho.2017.10.011
        • Arigami T
        • Matsushita D
        • Okubo K
        • Yanagita S
        • Ehi K
        • Sasaki K
        • et al.
        Response rate and prognostic impact of salvage chemotherapy after nivolumab in patients with advanced gastric cancer.
        Oncol. 2020; 98: 630-636https://doi.org/10.1159/000507219
        • Dietz A
        • Welslau M
        • Hahn D
        • Langer C
        • Bockmühl U
        • Müller-Huesmannet H
        • et al.
        HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany.
        J Clin Oncol. 2020; 38: 6532